Cabaletta Bio Q2: $203.2M cash, 9 patients enrolled, Grade 4 ICANS DLT resolved

Cabaletta Bio, Inc.

R&D expenses $23.4M (Q2 2023: $11.8M); G&A $6.9M (Q2 2023: $4.1M).
Cash, equivalents and ST investments $203.2M, expected to fund ops into H1 2026.
Nine patients enrolled across RESET program as of Aug 5; 22 U.S. sites now active.
LN patient with active refractory disease had Grade 4 ICANS DLT; IDMC recommended study proceed at current dose.
New Lonza CDMO agreement and expanded Cellares partnership for CABA-201 manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.